| Literature DB >> 29881306 |
Zhenzhen Yin1, Youyou Wang1, Yuemei Wu1, Ximei Zhang1, Fengming Wang1, Peiguo Wang1, Zhen Tao1, Zhiyong Yuan1.
Abstract
OBJECTIVE: The objective of the study was to describe the age distribution and to evaluate the role of prognostic value of age on survival in patients diagnosed with olfactory neuroblastoma (ONB). A population-based retrospective analysis was conducted.Entities:
Keywords: age distribution; esthesioneuroblastoma; olfactory neuroblastoma; prognosis
Year: 2018 PMID: 29881306 PMCID: PMC5985786 DOI: 10.2147/CMAR.S151945
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Patients’ characteristics and treatment data
| Variables | Case |
|---|---|
| Age (years) | 54 (1–91) |
| ≤60 | 314 (36%) |
| >60 | 562 (67%) |
| Racial | |
| White | 692 (79%) |
| Black | 77 (9%) |
| Others | 107 (12%) |
| Gender | |
| Male | 500 (57%) |
| Female | 376 (43%) |
| Primary site | |
| Nasal cavity | 668 (76%) |
| Nasal sinus | 208 (24%) |
| SEER stage | |
| Localized | 190 (22%) |
| Regional | 350 (40%) |
| Distant | 257 (29%) |
| Unknown | 79 (9%) |
| Diagnosis year | |
| ≥2000 | 623 (71%) |
| <2000 | 253 (29%) |
| Surgery | |
| Yes | 719 (82%) |
| No | 157 (18%) |
| Surgery type | |
| Gross total resection | 215 (30%) |
| Partial resection | 311 (43%) |
| Surgery NOS | 193 (27%) |
| Radiotherapy | |
| Yes | 595 (68%) |
| No/unknown | 281 (32%) |
| Chemotherapy | |
| Yes | 247 (28%) |
| No/unknown | 629 (72%) |
Abbreviations: NOS, not otherwise specified; SEER, Surveillance, Epidemiology, and End Results.
Figure 1Age distribution of all the patients.
Results of univariate analysis
| Factors | Overall survival
| Cancer-specific survival
| ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Gender (female vs male) | 1.430 (1.148–1.782) | 0.001 | 1.284 (0.984–1.675) | 0.065 |
| Age (continuous variable) | 1.034 (1.026–1.041) | 0.000 | 1.018 (1.010–1.027) | 0.000 |
| Racial (non-White vs White) | 1.066 (0.821–1.385) | 0.629 | 0.887 (0.723–1.088) | 0.249 |
| Primary site (sinus vs nasal cavity) | 0.938 (0.764–1.252) | 0.860 | 1.076 (0.802–1.443) | 0.627 |
| SEER (regional vs localized) | 1.816 (1.319–2.501) | 0.000 | 3.547 (2.081–6.046) | 0.000 |
| SEER (distant vs localized) | 4.302 (3.108–5.955) | 0.000 | 9.170 (5.376–15.641) | 0.000 |
| Surgery (no vs yes) | 2.790 (2.184–3.564) | 0.000 | 2.480 (1.842–3.338) | 0.000 |
| Surgery type (partial resection vs GTR) | 0.860 (0.619–1.193) | 0.336 | 0.818 (0.543–1.233) | 0.338 |
| Radiotherapy (no/unknown vs yes) | 1.058 (0.839–1.335) | 0.591 | 0.978 (0.736–1.299) | 0.876 |
Abbreviations: GTR, gross total resection; HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.
Results of multivariate analysis
| Factors | Overall survival
| Cancer-specific survival
| ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Gender (female vs male) | 1.363 (1.092–1.700) | 0.006 | 1.293 (0.973–1.719) | 0.077 |
| Age (continuous variable) | 1.031 (1.024–1.039) | 0.000 | 1.016 (1.008–1.025) | 0.000 |
| SEER stage (regional vs localized) | 1.691 (1.227–2.331) | 0.000 | 3.276 (1.919–5.592) | 0.000 |
| SEER stage (distant vs localized) | 3.983 (2.866–5.533) | 0.000 | 8.111 (4.727–13.918) | 0.000 |
| Surgery (no vs yes) | 2.059 (1.601–2.647) | 0.000 | 2.202 (1.596–3.038) | 0.002 |
Abbreviations: HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.
Figure 2OS curves of patients aged >60 and ≤60 years.
Notes: (A) Overall patients. (B) Patients treated with surgery. (C) Patients with loco-regional disease. (D) Patients with distant disease.
Abbreviation: OS, overall survival.
Figure 3CSS curves of patients aged >60 and ≤60 years.
Notes: (A) Overall patients. (B) Patients treated with surgery. (C) Patients with locoregional disease. (D) Patients with distant disease.
Abbreviation: CSS, cancer-specific survival.